Commentary | Published:

How similar do 'biosimilars' need to be?

Nature Biotechnology volume 22, pages 13571359 (2004) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    European Medicines Evaluation Agency. Guidelines on comparability of medicinal products containing biotechnology-derived proteins as active substance: Quality issues. EMEA/CPMP/BWP/3207/00/Rev 1. (EMEA, London, 2000).

  2. 2.

    European Medicines Evaluation Agency. Guidelines on comparability of medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. EMEA/CPMP/3097 /02/Final (EMEA, London, 2002).

  3. 3.

    Trends Biotechnol. 22, 406–410 (2004).

  4. 4.

    et al. N. Eng. J. Med. 351, 1403–1408 (2004).

  5. 5.

    Food Drug Law J. 54, 187–194 (1999).

  6. 6.

    Nat. Rev. Drug Discov. 1, 457–462 (2002).

  7. 7.

    Nat. Biotechnol. 21, 956–957 (2003).

Download references

Author information

Affiliations

  1. Huub Schellekens is at Utrecht University, Central Laboratory Animal Institute and Department of Innovation Studies, Bolognalaan 50, Utrecht, 3584 CJ, Netherlands. h.schellekens@gdl.uu.nl

    • Huub Schellekens

Authors

  1. Search for Huub Schellekens in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt1104-1357

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing